OncoVAX (Vaccinogen) is a personalized cancer vaccine that uses the patient’s own cancer cells to prevent tumor progression after surgery. Vaccinogen uses a proprietary method for dissociating and purifying cancer cells from a resected tumor, and the resulting vaccine is thought to induce a robust and functional immune response in the patient. To prepare the vaccine, autologous tumors are excised, enzymatically dissociated to separate tumor cells from healthy cells, and irradiated to render the tumor cells non-proliferating and non-tumorigenic, but metabolically active. Patients receive four intradermal immunizations over the span of six months, as per the OncoVAX protocol: two injections consisting of irradiated tumor cells compounded with a live-attenuated mycobacteria adjuvant, followed by two injections consisting of irradiated cells only.
Following promising results from a Phase IIIa trial, a confirmatory Phase IIIb trial in Stage II resected colon cancer was initiated in May 2015.
TABLE OF CONTENTS
4 Product Profiles
4 OncoVAX : Colorectal cancer (CRC)
LIST OF FIGURES
9 Figure 1: OncoVAX for colon cancer – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of OncoVAX for colon cancer
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of OncoVAX for colon cancer
13 Figure 4: OncoVAX sales for colon cancer in the US, 2016–25
LIST OF TABLES
5 Table 1: OncoVAX drug profile
6 Table 2: OncoVAX Phase III trial in colon cancer
8 Table 3: OncoVAX Phase III data in colon cancer
13 Table 4: OncoVAX sales for colon cancer in the US ($m), 2016–25
14 Table 5: Patients treated with OncoVAX in the US, 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.